FDA Fast Track for Female Testosterone Patch Questioned

Main Category: Public Health
Article Date: 29 Nov 2004 - 0:00 PDT

email to a friend   printer friendly   opinions  

The Food and Drug Administration (FDA) has granted a fast track review of testosterone patches for women with low sex drive, despite concerns about insufficient data and potentially misleading marketing by their manufacturer Proctor & Gamble, claim two articles in this week's BMJ.

The patch is the first drug to be assessed for a controversial condition called hypoactive sexual desire disorder. Proctor & Gamble claims that the patch can increase sexual activity by 74%, which has generated enthusiastic media coverage. It has also urged an international medical society, which it sponsors, to endorse the patch at the FDA regulatory hearing.

But the marketing has caused concern among some sex researchers by failing to state that in absolute terms, the patch may only increase sexual activity by one "episode," or less, per month.

Although an increase of one sexual episode a month may be of value clinically to some women, this is overshadowed by serious doubts about the long term safety of testosterone, say experts.

Rosemary Basson, one of the leading authorities in the field of women's sexual difficulties, says much caution is needed in prescribing testosterone to women. Meanwhile, others have raised serious questions about the disorder because women's sexual "symptoms" may often be healthy adaptive responses and should not be regarded as evidence of dysfunction……………. CONTINUES……….www.seniorjournal.com

• Additional
• References
• Citations